Jyseleca (Filgotinib)

Filgotinib selectively blocks Janus kinase 1 (JAK1), an enzyme that transmits signals from several pro‑inflammatory cytokines. By inhibiting JAK1, the drug dampens the downstream STAT signaling pathway, decreasing the production of inflammatory mediators that drive joint and intestinal inflammation.

The specific dose of Jyseleca is determined by the prescribing clinician based on the patient’s condition, disease severity, and individual health factors. Healthcare professionals follow the approved labeling and adjust the regimen as needed for safety and efficacy.

The safety of filgotinib in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, so it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their physician.

To request Jyseleca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jyseleca (filgotinib) is a selective JAK1 inhibitor, whereas some alternatives target multiple JAK isoforms (JAK1/2/3). This selectivity may offer a different safety profile, potentially reducing certain adverse events linked to broader JAK inhibition, but comparative efficacy and safety should be evaluated by the treating physician.

Jyseleca tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Jyseleca is taken orally, usually as a whole tablet with or without food, as directed by the prescribing healthcare professional. The tablet should be swallowed whole and not crushed or chewed unless otherwise instructed.

Serious risks include opportunistic infections such as tuberculosis, herpes zoster reactivation, venous thromboembolism, and potential malignancies. Patients should be monitored regularly for signs of infection, clotting events, and any unexpected symptoms, and clinicians should assess individual risk factors before initiating therapy.

Jyseleca is contraindicated in patients with active serious infections, known hypersensitivity to filgotinib or any excipients, and those receiving live vaccines. Caution is also advised for individuals with severe hepatic impairment, a history of thrombotic events, or uncontrolled cardiovascular disease.